These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9086464)

  • 1. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human.
    Eleopra R; Tugnoli V; Rossetto O; Montecucco C; De Grandis D
    Neurosci Lett; 1997 Mar; 224(2):91-4. PubMed ID: 9086464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting.
    Eleopra R; Tugnoli V; Quatrale R; Gastaldo E; Rossetto O; De Grandis D; Montecucco C
    Clin Neurophysiol; 2002 Aug; 113(8):1258-64. PubMed ID: 12140005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C.
    Morbiato L; Carli L; Johnson EA; Montecucco C; Molgó J; Rossetto O
    Eur J Neurosci; 2007 May; 25(9):2697-704. PubMed ID: 17561839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F.
    Eleopra R; Tugnoli V; Quatrale R; Rossetto O; Montecucco C; Dressler D
    Neurotox Res; 2006 Apr; 9(2-3):127-31. PubMed ID: 16785109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans.
    Eleopra R; Tugnoli V; Rossetto O; De Grandis D; Montecucco C
    Neurosci Lett; 1998 Nov; 256(3):135-8. PubMed ID: 9855358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons.
    Foran PG; Mohammed N; Lisk GO; Nagwaney S; Lawrence GW; Johnson E; Smith L; Aoki KR; Dolly JO
    J Biol Chem; 2003 Jan; 278(2):1363-71. PubMed ID: 12381720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin.
    Marion MH; Humberstone M; Grunewald R; Wimalaratna S
    Pract Neurol; 2016 Aug; 16(4):288-95. PubMed ID: 26976927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different types of botulinum toxin in humans.
    Eleopra R; Tugnoli V; Quatrale R; Rossetto O; Montecucco C
    Mov Disord; 2004 Mar; 19 Suppl 8():S53-9. PubMed ID: 15027055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients.
    Kutschenko A; Weisemann J; Kollewe K; Fiedler T; Alvermann S; Böselt S; Escher C; Garde N; Gingele S; Kaehler SB; Karatschai R; Krüger THC; Sikorra S; Tacik P; Wegner F; Wollmann J; Bigalke H; Wohlfarth K; Rummel A
    Clin Neurophysiol; 2019 Jun; 130(6):1066-1073. PubMed ID: 30871800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.
    Rollnik JD; Matzke M; Wohlfarth K; Dengler R; Bigalke H
    Eur Neurol; 2000; 43(1):9-12. PubMed ID: 10601802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacodynamics of a novel recombinant botulinum toxin E (rBoNT-E): Results of a phase 1 study in healthy male subjects compared with abobotulinumtoxinA (Dysport®).
    Pons L; Vilain C; Volteau M; Picaut P
    J Neurol Sci; 2019 Dec; 407():116516. PubMed ID: 31655410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A].
    Cardoso F
    Arq Neuropsiquiatr; 2003 Sep; 61(3A):607-10. PubMed ID: 14513166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical duration of action of different botulinum toxin types in humans.
    Eleopra R; Rinaldo S; Montecucco C; Rossetto O; Devigili G
    Toxicon; 2020 May; 179():84-91. PubMed ID: 32184153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Botulism toxin in practice].
    Durand A; Serment G
    Ann Readapt Med Phys; 2003 Jul; 46(6):386-8. PubMed ID: 12928147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.
    Adler M; Keller JE; Sheridan RE; Deshpande SS
    Toxicon; 2001; 39(2-3):233-43. PubMed ID: 10978741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles.
    Priori A; Berardelli A; Mercuri B; Manfredi M
    Brain; 1995 Jun; 118 ( Pt 3)():801-7. PubMed ID: 7600096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions.
    Aoki KR; Guyer B
    Eur J Neurol; 2001 Nov; 8 Suppl 5():21-9. PubMed ID: 11851731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurophysiological observations on the effects of botulinum toxin treatment in patients with dystonic blepharospasm.
    Valls-Sole J; Tolosa ES; Ribera G
    J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):310-3. PubMed ID: 1647444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches.
    Coffield JA; Bakry N; Zhang RD; Carlson J; Gomella LG; Simpson LL
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1489-98. PubMed ID: 9067339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.
    Schlereth T; Mouka I; Eisenbarth G; Winterholler M; Birklein F
    Auton Neurosci; 2005 Feb; 117(2):120-6. PubMed ID: 15664565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.